Technological advancements in modular and automated platforms are revolutionizing non-biologics manufacturing in the pharmaceutical sector. With the global rise in non-biologics demand, there's an increasing push for technologies that ensure regulatory compliance, enhance productivity, and cut down waste. The Pharma 4.0 trend, which incorporates artificial intelligence (AI), the Internet of Things (IoT), and big data analytics, is central to these advancements. These innovations promise to boost efficiency, enable early error detection, and streamline processes by reducing human intervention. As some technologies gain widespread adoption and others, like robotics, gradually increase, the industry is set to experience transformative changes in production speed, precision, and cost-effectiveness.
Download Now
What strategic imperatives are driving the development of modular and automated platforms in pharmaceutical manufacturing?
Industry Convergence
Digital tools like AI and smart sensors are enhancing process accuracy, streamlining operations, and enabling predictive maintenance for error-free manufacturing.
Disruptive Technologies
Modular technologies are revolutionizing manufacturing by reducing downtime and enabling rapid scale-up, boosting efficiency and productivity.
Geopolitical Chaos
Automation and modular equipment are addressing supply chain disruptions and improving safety, ensuring business continuity and minimizing contamination risks.
Key Strategic Partnerships and Investments of 2024
-
Nippon Express Holdings and Controlant launched real-time monitoring for pharmaceuticals, integrating NX's e-NX system with Controlant’s data logger for better cargo status and temperature control.
-
Apertus Pharmaceuticals and the API Innovation Center partnered to manufacture lomustine using advanced continuous flow biomanufacturing technologies funded by the API Innovation Center.
-
Hovione and GEA introduced the ConsiGma CDC Flex and a new lab-scale continuous tableting rig in Portugal, making it available globally. GEA will also supply lab-scale feeding and blending systems for R&D.
Explore the emerging technologies, key industry players, and the funding landscape shaping the future of pharmaceutical manufacturing in our latest Frost & Sullivan analysis. Download now for a detailed perspective!
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
Upon completing the dialog session, you will receive a $1,000 honorarium as a token of our appreciation, which can be used towards the purchase of our products or services.
